ATE456579T1 - Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung - Google Patents
Angiopoietin-like 4 protein hemmer kombinationen und deren verwendungInfo
- Publication number
- ATE456579T1 ATE456579T1 AT05790352T AT05790352T ATE456579T1 AT E456579 T1 ATE456579 T1 AT E456579T1 AT 05790352 T AT05790352 T AT 05790352T AT 05790352 T AT05790352 T AT 05790352T AT E456579 T1 ATE456579 T1 AT E456579T1
- Authority
- AT
- Austria
- Prior art keywords
- angiopoietin
- protein inhibitor
- inhibitor combinations
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58978204P | 2004-07-20 | 2004-07-20 | |
PCT/US2005/025734 WO2006014729A2 (en) | 2004-07-20 | 2005-07-19 | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE456579T1 true ATE456579T1 (de) | 2010-02-15 |
Family
ID=35787710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05790352T ATE456579T1 (de) | 2004-07-20 | 2005-07-19 | Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung |
Country Status (23)
Country | Link |
---|---|
US (2) | US7740846B2 (de) |
EP (3) | EP1771474B1 (de) |
JP (2) | JP4947717B2 (de) |
KR (1) | KR101254815B1 (de) |
CN (2) | CN101044164A (de) |
AT (1) | ATE456579T1 (de) |
AU (2) | AU2005269716B2 (de) |
BR (1) | BRPI0513534A (de) |
CA (1) | CA2574758A1 (de) |
CY (1) | CY1109931T1 (de) |
DE (1) | DE602005019167D1 (de) |
DK (1) | DK1771474T3 (de) |
ES (1) | ES2339789T3 (de) |
IL (1) | IL180725A0 (de) |
MX (1) | MX2007000784A (de) |
NO (1) | NO20070951L (de) |
NZ (1) | NZ552956A (de) |
PL (1) | PL1771474T3 (de) |
PT (1) | PT1771474E (de) |
RU (1) | RU2392966C2 (de) |
SI (1) | SI1771474T1 (de) |
WO (1) | WO2006014729A2 (de) |
ZA (1) | ZA200701183B (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7883720B2 (en) * | 2003-07-09 | 2011-02-08 | Wisconsin Alumni Research Foundation | Charge-dynamic polymers and delivery of anionic compounds |
MX2007000784A (es) | 2004-07-20 | 2007-04-09 | Genentech Inc | Inhibidores de proteina 4 tipo angiopoietina, combinaciones y su uso. |
US7371384B2 (en) | 2004-07-20 | 2008-05-13 | Genentech, Inc. | Compositions and methods of using angiopoietin-like 4 protein antibody |
US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
JP5366406B2 (ja) * | 2005-01-07 | 2013-12-11 | レキシコン ファーマシューティカルズ インコーポレーテッド | アンジオポエチン様タンパク質4(angptl4)に対するモノクローナル抗体 |
US8734851B2 (en) * | 2005-04-29 | 2014-05-27 | Wisconsin Alumni Research Foundation | Localized delivery of nucleic acid by polyelectrolyte assemblies |
MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
KR100962301B1 (ko) | 2006-11-03 | 2010-06-11 | 재단법인서울대학교산학협력재단 | 자궁경부암을 위한 치료용 조성물 |
EP3095455A1 (de) * | 2006-12-19 | 2016-11-23 | Genentech, Inc. | Vegf-spezifische antagonisten für adjuvans- und neoadjuvanstherapie und zur therapie von tumoren im frühstadium |
US8834918B2 (en) * | 2007-01-22 | 2014-09-16 | Wisconsin Alumni Research Foundation | Modified multilayered film |
JP2010532385A (ja) * | 2007-07-02 | 2010-10-07 | ユ,ミン | 複合的癌治療の方法、組成物および標的 |
US20090105375A1 (en) * | 2007-10-09 | 2009-04-23 | Lynn David M | Ultrathin Multilayered Films for Controlled Release of Anionic Reagents |
US8126437B1 (en) | 2008-01-24 | 2012-02-28 | Invent Again | Ubiquitous voice messaging |
US8324333B2 (en) * | 2008-06-05 | 2012-12-04 | Wisconsin Alumni Research Foundation | Anionic charge-dynamic polymers for release of cationic agents |
WO2010009346A2 (en) * | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
CN105214086B (zh) | 2008-11-22 | 2019-09-27 | 霍夫曼-拉罗奇有限公司 | 抗-vegf抗体与化学治疗联合用于治疗乳腺癌的应用 |
KR101426125B1 (ko) | 2009-07-06 | 2014-08-06 | 에르피오 세러퓨틱스 인코포레이티드 | 암 세포의 전이 예방을 위한 화합물, 조성물 및 방법 |
EP2488640B1 (de) * | 2009-10-14 | 2018-09-26 | Nanyang Technological University | Antiproliferationsmittel |
DK2521556T3 (en) | 2010-01-08 | 2018-08-13 | Ionis Pharmaceuticals Inc | MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION |
US9475850B2 (en) | 2010-06-05 | 2016-10-25 | The Uab Research Foundation | Methods for treatment of nephrotic syndrome and related conditions |
US9139629B2 (en) | 2010-06-05 | 2015-09-22 | The Uab Research Foundation | Methods for treatment of nephrotic syndrome and related conditions |
EP3311835B1 (de) * | 2010-07-12 | 2021-03-24 | Threshold Pharmaceuticals Inc. | Verabreichung von hypoxie-aktivierten prodrugs und antiangiogenen wirkstoffen zur behandlung von krebs |
US20140004209A1 (en) | 2010-12-22 | 2014-01-02 | Genentech, Inc. | Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms |
EP2734199B1 (de) | 2011-07-22 | 2022-11-16 | Pacylex Pharmaceuticals Inc. | Synthetische letalität und behandlung von krebs |
WO2013022406A1 (en) * | 2011-08-08 | 2013-02-14 | Nanyang Technological University | Angiopoietin-like 4 and its use in modulating cell leakiness |
CA2850830A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
SG10201610869TA (en) | 2012-06-26 | 2017-02-27 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti |
EP2885319B1 (de) * | 2012-08-14 | 2019-10-09 | Nanyang Technological University | Angiopoietin-like-4-antikörper und verfahren zu seiner verwendung in der krebsbehandlung |
US9259435B2 (en) | 2012-08-31 | 2016-02-16 | W. L. Gore & Associates, Inc. | Reactive oxidative species generating materials and methods of use |
KR102496892B1 (ko) * | 2012-10-30 | 2023-02-06 | 페이실렉스 파마슈티컬스 인코포레이티드 | 암의 합성치사 및 치료 |
KR101407730B1 (ko) * | 2012-11-23 | 2014-06-12 | 인하대학교 산학협력단 | 안지오포이에틴-4 단백질을 유효성분으로 포함하는 발기부전의 예방 또는 치료용 조성물 |
GB201301313D0 (en) | 2013-01-25 | 2013-03-06 | Univ Singapore | Respiratory Tract Infections |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
EP3828275A1 (de) | 2013-05-01 | 2021-06-02 | Ionis Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur modulation der ttr-expression |
DK3087183T3 (da) | 2013-12-24 | 2020-09-14 | Ionis Pharmaceuticals Inc | Modulation af angiopoietin-3-lignende ekspression |
JP6483148B2 (ja) | 2014-03-14 | 2019-03-13 | エアーピオ セラピューティクス インコーポレイテッド | HPTP−β阻害剤 |
PL3137605T3 (pl) * | 2014-05-01 | 2021-04-19 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji białka angiopoetynopodobnego 3 |
US9988443B2 (en) | 2014-08-07 | 2018-06-05 | Novartis Ag | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use |
MA40512A (fr) * | 2014-08-07 | 2021-03-24 | Novartis Ag | Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants |
US11788145B2 (en) | 2015-07-17 | 2023-10-17 | Pacylex Pharmaceuticals Inc. | Epigeneiic silencing of NMT2 |
JP6959924B2 (ja) | 2015-09-23 | 2021-11-05 | エアーピオ ファーマシューティカルズ, インコーポレイテッド | Tie−2の活性化物質を用いる眼内圧を処置する方法 |
CN106596979B (zh) * | 2017-02-28 | 2018-10-09 | 汉氏联合(天津)干细胞研究院有限公司 | 一种用于帕金森综合症检测的试剂盒及其检测方法 |
AU2019382087A1 (en) * | 2018-11-13 | 2021-05-20 | Lipigon Pharmaceuticals Ab | ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolism |
WO2020223209A1 (en) | 2019-04-29 | 2020-11-05 | Aerpio Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
EP4072562A4 (de) * | 2019-12-09 | 2023-12-20 | Empirico Inc. | Oligonukleotide zur behandlung von mit angiopoietin-like 4 (angptl4) assoziierten krankheiten |
CN112611877B (zh) * | 2020-12-31 | 2022-09-16 | 四川大学华西医院 | 一款利用angptl4预测急性呼吸窘迫综合征患病及预后的试剂盒 |
CN113797355B (zh) * | 2021-10-14 | 2023-07-21 | 四川大学华西医院 | 具有滑膜炎症抑制功能的纳米材料的制备方法及应用 |
Family Cites Families (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (de) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotikum C-15003 PHO und seine Herstellung |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
EP0206448B1 (de) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (de) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformationsvektoren für Hefe Yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0546073B1 (de) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
CA2405246A1 (en) * | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Hiv感染治療のための異種複合抗体 |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
EP1167384B1 (de) | 1992-10-28 | 2006-12-13 | Genentech, Inc. | HVEGF Rezeptor als VEGF Antagonist |
PL174721B1 (pl) | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
US5641756A (en) * | 1993-07-27 | 1997-06-24 | Hybridon, Inc. | Modified VEGF oligonucleotides |
US5643755A (en) * | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5650490A (en) * | 1994-10-07 | 1997-07-22 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 2 |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
EP2301580B1 (de) | 1997-04-07 | 2012-01-18 | Genentech, Inc. | Behälter mit anti-VEGF Antikörpern |
EP1787999B1 (de) | 1997-04-07 | 2010-08-04 | Genentech, Inc. | Anti-VEGF Antikörper |
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US6348350B1 (en) * | 1997-09-19 | 2002-02-19 | Genentech, Inc. | Ligand homologues |
US20030207375A1 (en) | 1997-10-24 | 2003-11-06 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU1931599A (en) | 1997-12-19 | 1999-07-12 | Zymogenetics Inc. | Angiopoietin homolog, dna encoding it, and method of making it |
JP2002516067A (ja) | 1998-03-02 | 2002-06-04 | ミレニアム・フアーマシユーチカルズ・インコーポレーテツド | 新規fdrgタンパク質および核酸分子、ならびにそのための用途 |
EP1088071A4 (de) * | 1998-06-16 | 2005-03-02 | Human Genome Sciences Inc | 94 sekretierte menschliche proteine |
WO1999067382A2 (en) | 1998-06-24 | 1999-12-29 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
ATE377449T1 (de) | 1998-07-15 | 2007-11-15 | Max Planck Gesellschaft | Polyelektrolythüllen auf biologischen templaten |
US6375447B1 (en) | 1998-09-29 | 2002-04-23 | Cq Inc. | Apparatus for dewatering and pelletizing particulate fuel |
WO2001057188A2 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001054477A2 (en) | 2000-01-25 | 2001-08-02 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001053455A2 (en) | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
JP2000308488A (ja) | 1999-02-23 | 2000-11-07 | Herikkusu Kenkyusho:Kk | 血管新生に関連するタンパク質および該タンパク質をコードする遺伝子 |
AU3391200A (en) | 1999-03-04 | 2000-09-21 | Corixa Corporation | Compositions and methods for breast cancer therapy and diagnosis |
EP1175439A4 (de) | 1999-04-09 | 2002-10-09 | Human Genome Sciences Inc | 49 humane sekretierte proteine |
ES2265931T3 (es) | 1999-04-16 | 2007-03-01 | Genentech, Inc. | Variantes del factor de crecimiento celular endotelial vascular (vegf) y sus usos. |
US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
WO2001002429A2 (en) | 1999-07-02 | 2001-01-11 | Bayer Aktiengesellschaft | Angiopoietin-6 and uses thereof |
AU6605900A (en) | 1999-07-16 | 2001-02-05 | Hyseq, Inc. | Novel angiopoietin materials and methods |
EP1196576A2 (de) | 1999-07-20 | 2002-04-17 | Curagen Corporation | Sekretionspolypeptiden und übereinstimmende polynukleotiden |
US20030207348A1 (en) * | 1999-07-20 | 2003-11-06 | Shimkets Richard A. | Polypeptides and polynucleotides encoding same |
WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
CN1315451A (zh) | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人血管形成素类似因子45和编码这种多肽的多核苷酸 |
AU2001249929A1 (en) | 2000-04-07 | 2001-10-23 | Dana-Farber Cancer Institute Inc. | Fdrg proteins and nucleic acid molecules and uses therefor |
PT1292335E (pt) | 2000-06-23 | 2007-08-13 | Bayer Schering Pharma Ag | Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii) |
US6673545B2 (en) * | 2000-07-28 | 2004-01-06 | Incyte Corporation | Prostate cancer markers |
CN1170850C (zh) * | 2000-09-19 | 2004-10-13 | 上海市肿瘤研究所 | 人血管生成素样蛋白和编码序列及其用途 |
US20030144498A1 (en) * | 2000-10-16 | 2003-07-31 | Audrey Goddard | TIE ligand homologues |
WO2002077013A2 (en) | 2001-03-27 | 2002-10-03 | Human Genome Sciences, Inc. | Human secreted proteins |
US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
ES2464532T3 (es) | 2001-04-19 | 2014-06-03 | The Scripps Research Institute | Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa |
US20030170891A1 (en) * | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
WO2002101039A1 (en) | 2001-06-08 | 2002-12-19 | Sankyo Company, Limited | Method of testing drug for treating or preventing diseases such as hyperlipemia |
WO2003010205A1 (en) | 2001-07-26 | 2003-02-06 | Duke University Medical Center | Genes induced by hypoxia |
CA2459219A1 (en) | 2001-09-17 | 2003-03-27 | Protein Design Labs, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
US20050123925A1 (en) * | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP1539985A4 (de) | 2001-11-05 | 2006-06-28 | Curagen Corp | Therapeutische polypeptide, diese codierende nukleinsäuren sowie verwendungsverfahren |
US20040038230A1 (en) | 2001-11-05 | 2004-02-26 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
AU2002348286B2 (en) | 2001-11-16 | 2008-04-03 | Genentech, Inc. | Composition comprising and method of using angiopoietin-like protein 3 Angptl3 |
WO2003048185A2 (en) | 2001-11-30 | 2003-06-12 | Genvec, Inc. | Angiopioetin related factors |
EP1997829A1 (de) | 2001-12-21 | 2008-12-03 | Human Genome Sciences, Inc. | Albumin Fusionsproteine |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
US20050239706A1 (en) * | 2003-10-31 | 2005-10-27 | Washington University In St. Louis | Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject |
CA2499791A1 (en) * | 2004-03-30 | 2005-09-30 | F. Hoffmann-La Roche Ag | Angptl4/fiaf as marker for ppardelta modulation |
MX2007000784A (es) | 2004-07-20 | 2007-04-09 | Genentech Inc | Inhibidores de proteina 4 tipo angiopoietina, combinaciones y su uso. |
US7371384B2 (en) | 2004-07-20 | 2008-05-13 | Genentech, Inc. | Compositions and methods of using angiopoietin-like 4 protein antibody |
JP5366406B2 (ja) * | 2005-01-07 | 2013-12-11 | レキシコン ファーマシューティカルズ インコーポレーテッド | アンジオポエチン様タンパク質4(angptl4)に対するモノクローナル抗体 |
-
2005
- 2005-07-19 MX MX2007000784A patent/MX2007000784A/es active IP Right Grant
- 2005-07-19 DE DE602005019167T patent/DE602005019167D1/de active Active
- 2005-07-19 PT PT05790352T patent/PT1771474E/pt unknown
- 2005-07-19 SI SI200530979T patent/SI1771474T1/sl unknown
- 2005-07-19 DK DK05790352.8T patent/DK1771474T3/da active
- 2005-07-19 EP EP05790352A patent/EP1771474B1/de not_active Revoked
- 2005-07-19 ZA ZA200701183A patent/ZA200701183B/en unknown
- 2005-07-19 KR KR1020077003872A patent/KR101254815B1/ko active IP Right Grant
- 2005-07-19 JP JP2007522697A patent/JP4947717B2/ja not_active Expired - Fee Related
- 2005-07-19 ES ES05790352T patent/ES2339789T3/es active Active
- 2005-07-19 RU RU2007106076/14A patent/RU2392966C2/ru active
- 2005-07-19 NZ NZ552956A patent/NZ552956A/en not_active IP Right Cessation
- 2005-07-19 CA CA002574758A patent/CA2574758A1/en not_active Abandoned
- 2005-07-19 BR BRPI0513534-6A patent/BRPI0513534A/pt not_active Application Discontinuation
- 2005-07-19 AT AT05790352T patent/ATE456579T1/de active
- 2005-07-19 EP EP09013335A patent/EP2172482A1/de not_active Withdrawn
- 2005-07-19 WO PCT/US2005/025734 patent/WO2006014729A2/en active Application Filing
- 2005-07-19 CN CNA2005800316893A patent/CN101044164A/zh active Pending
- 2005-07-19 EP EP10010294.6A patent/EP2361931B1/de active Active
- 2005-07-19 US US11/185,215 patent/US7740846B2/en active Active
- 2005-07-19 PL PL05790352T patent/PL1771474T3/pl unknown
- 2005-07-19 AU AU2005269716A patent/AU2005269716B2/en active Active
- 2005-07-19 CN CN2012100589479A patent/CN102641503A/zh active Pending
-
2006
- 2006-09-28 US US11/540,884 patent/US20070026002A1/en not_active Abandoned
-
2007
- 2007-01-16 IL IL180725A patent/IL180725A0/en unknown
- 2007-02-19 NO NO20070951A patent/NO20070951L/no not_active Application Discontinuation
-
2010
- 2010-03-30 CY CY20101100299T patent/CY1109931T1/el unknown
-
2011
- 2011-03-30 AU AU2011201436A patent/AU2011201436A1/en not_active Withdrawn
- 2011-08-10 JP JP2011175420A patent/JP2012017331A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE456579T1 (de) | Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung | |
DE602006018057D1 (de) | Substituierte chinolone und verwendungsverfahren | |
DE602005026105D1 (de) | Verwendung von agonisten und antagonisten von interleukin-33 (il-33) | |
CY1120257T1 (el) | ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΜΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ JANUS | |
ATE538136T1 (de) | Antikörper gegen connective tissue growth factor | |
ATE511857T1 (de) | Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs | |
IL187343A0 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
ATE552000T1 (de) | Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs | |
BRPI0618488A2 (pt) | proteìnas de fusão de ìntron de fator de crescimento de hepatócito | |
DE60324094D1 (de) | Verwendung einer proteinkinase a-inaktivierenden verbindung in einer kosmetisch verträglichen zusammensetzung zur aufhellung der haut | |
ATE527998T1 (de) | Illudin-analoga als krebsmittel | |
TW200738657A (en) | Thiazole compounds and methods of use | |
ATE450615T1 (de) | Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen | |
WO2007053622A3 (en) | Methods for modulating ppar activity to treat diseases caused by mutations in the cftr gene | |
CO6270257A2 (es) | Derivados de piridazinona | |
HK1118210A1 (en) | Compositions and methods for treating cardiac conditions | |
EP1912674A4 (de) | Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür | |
DE60329756D1 (de) | Mitotische kinesin-hemmer | |
DK1615952T3 (da) | Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler | |
ATE512146T1 (de) | Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen | |
ATE335719T1 (de) | Polyamine und ihre therapeutische verwendung | |
EA200702094A1 (ru) | Производные гетероарилмочевины, пригодные для ингибирования chk1 | |
BR0313588A (pt) | Métodos para o tratamento da demência com base em apo e genótipo | |
BRPI0821114A2 (pt) | Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer | |
ATE537838T1 (de) | Kombinationstherapie mit kloretazin(tm) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1771474 Country of ref document: EP |